Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Gleason Score</td><td align="center">0.03</td></tr><tr><td align="left">PSA</td><td align="center">0.41</td></tr><tr><td align="left">T-Stage</td><td align="center">0.4</td></tr><tr><td align="left">PAP</td><td align="center">0.001</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Predictors of Biochemical Failure (multivariate analysis).

Journal of Oncology

tab2

Table 2

Table 2: Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy 

Table 2 | Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy 